Clinician vs Patient Reporting of Baseline and Postbaseline Symptoms for Adverse Event Assessment in Cancer Clinical Trials Atkinson, Thomas M. , Dueck, Amylou C. , Satele, Daniel V. ... - - JAMA Oncol - 2020 Manuscript - Secondary - Meta-Analysis - Health Outcome - N0591
Phase III Double-Blind, Placebo-Controlled Study of Gabapentin for the Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy, NCCTG N08C3 (Alliance) Barton, Debra L. , Thanarajasingam, Gita , Sloan, Jeff A. ... - - Cancer - 2014 Manuscript - Primary - Primary - Symptom Inter - N08C3
Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Basch, Ethan , Becker, Claus , Rogak, Lauren J , Schrag, Deborah ... - - Clin Trials - 2020 Manuscript - Secondary-not-in-original - Primary - Health Outcome - A091105
Development of a Composite Scoring Algorithm for the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) (Alliance) Basch, Ethan , Becker, Claus , Rogak, Lauren , Spears, Patricia ... - ISOQOL - - 2019 Abstract - Secondary-not-in-original - Primary - Health Outcome - A091105
Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial Basch, Ethan , Stover, Angela M. , Schrag, Deborah , Chung, Arlene ... - - JCO Clin Cancer Inform - 2020 Manuscript - Primary - Primary - Health Outcome - AFT-39
Incorporating Clinicians’ CTCAE Grades as Auxiliary Variables When Imputing Patients’ PRO-CTCAE Scores via Multiple Imputation in Alliance A091105 Mazza, Gina L. , Petersen, Molly M. , Rogak, Lauren J. ... - ISOQOL - Quality of Life Research - 2020 Abstract - Secondary - Primary - Health Outcome - A151925 , A091105
A novel approach of longitudinal adverse event evaluation in oncology clinical trials: the Toxicity over Time (ToxT) analysis of clinical trials N9741 and 979254 (Alliance) Thanarajasingam, Gita , Atherton, Pamela J. , Novotny, Paul J. ... - - Lancet Oncol. - 2016 Manuscript - Secondary-not-in-original - Primary - Health Outcome - N9741 , NCCTG-97-92-54
Beyond maximum grade: A novel, longitudinal toxicity over time (ToxT) adverse event analysis of lenalidomide in follicular lymphoma in Alliance A151617 Thanarajasingam, Gita , Dueck, Amylou , Novotny, Paul J. ... - ICML - Hematol Oncol - 2017 Abstract - Primary - Primary - Health Outcome - CALGB-50401 , A151617
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in CALGB 50401 (Alliance) Thanarajasingam, Gita , Leonard, John P. , Witzig, Thomas E. ... - - Lancet Haematol - 2020 Manuscript - No-Endpoint - Other - Health Outcome - A151617 , CALGB-50401
Comparison of chemotherapy toxicity over time according to age and performance status in patients with advanced non-small cell lung cancer: a toxicity over time analysis of CALGB 9730 (Alliance A151729) Wong, Melisa L. , Gao, Junheng , Thanarajasingam, Gita ... - SIOG (ISOG) - J Geriatric Oncol - 2018 Abstract - Primary - Primary - Older Adult - CALGB-9730
Expanding beyond maximum grade: Chemotherapy toxicity over time by age and performance status in advanced non-small cell lung cancer in CALGB 9730 (Alliance A151729). Wong, Melisa L , Gao, Junheng , Thanarajasingam, Gita , Sloan, Jeff A ... - - Oncologist - 2020 Manuscript - Primary - Primary - Older Adult - A151729 , CALGB-9730